Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Amgen reports positive top-line results from Phase III trial of evolocumab combination Amgen has reported positive results from the Phase III YUKAWA-2 trial of evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol.
Drug Research > Drug Discovery & Development > News
Amerigen, Menovo partner to develop generic pharmaceuticals for US market By PBR Staff Writer
US-based Amerigen Pharmaceuticals has entered into a collaboration agreement with Chinese firm Ningbo Menovo Pharmaceutical (Menovo) to develop generic pharmaceuticals, primarily targeting the US market.
Drug Research > Drug Discovery & Development > News Sorrento secures NIH Grant to advance immunotherapy for IPF treatment By PBR Staff Writer
US-based clinical oncology firm Sorrento Therapeutics has received a Small Business Innovation Research (SBIR) Phase I grant to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) to treat Idiopathic Pulmonary Fibrosis (IPF).
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Baxter reports positive top-line results from Phase III trial of BAX 855
Nektar Therapeutics reports Baxter International has announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.
Drug Research > Drug Discovery & Development > News
Aldea Pharmaceuticals closes $24m series B financing
Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, has announced that it has closed a $24 million Series B equity financing.
Drug Research > Drug Discovery & Development > News
Advaxis, Merck collaborate for new immune therapies for prostate cancer treatment
By PBR Staff Writer
Advaxis has entered into a clinical trial collaboration agreement with Merck to evaluate an investigational combination of two new immunotherapy candidates ADXS-PSA and pembrolizumab to treat patients with advanced prostate cancer.
Drug Research > Drug Discovery & Development > News
Glenmark starts IND-enabling studies of new bispecific antibody
By PBR Staff Writer
Glenmark Pharmaceuticals has started the investigational new drug (IND)-enabling studies of a new bispecific antibody.
Drug Research > Drug Discovery & Development > News
Mitsubishi Tanabe Pharma, Astrazeneca partner on diabetic nephropathy research
By PBR Staff Writer
Japan-based Mitsubishi Thnabe Pharma (MTPC) has collaborated with AstraZeneca to carry out research on diabetic nephropathy.
Drug Research > Drug Discovery & Development > News
FDA approves GSK’s Arnuity Ellipta to treat asthma in US
By PBR Staff Writer
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) fluticasone furoate inhalation powder, to be sold as Arnuity Ellipta, as a daily-once corticosteroid for treatment of asthma in patients aged above twelve years in the US.
Drug Research > Drug Discovery & Development > News
Softigel - Manufacturers of Softgel Pharmaceutical Products
Softigel develops and manufactures softgel (soft gelatin) capsules, advanced drug delivery technologies, nutritional supplements, as well as veterinary, cosmetic and pharmaceutical products. Softgels are an effective delivery system for oral drugs, especially those with low solubility and/or permeability (BCS classes II, III and IV). We are Procaps' stategic business division for contract manufacturing services.
Drug Research > Drug Discovery & Development > Suppliers
Roche’s Avastin plus chemotherapy gets FDA approval for cervical cancer treatment
By PBR Staff Writer
Roche has received approval from the US Food and Drug Administration (FDA) for Avastin (bevacizumab) in combination with paclitaxel and cisplatin or paclitaxel and topotecan to treat women with persistent, recurrent or metastatic carcinoma of the cervix.
Drug Research > Drug Discovery & Development > News
Nuvilex reports combined results of the initial Phase 1/2 clinical trial and second Phase 2 clinical trial of Cell-in-a-Box
Nuvilex has announced that its partner, Austrianova, has reported the results from the second Phase 2 clinical trial combining the Cell-in-a-Box cellulose-based live cell encapsulation technology plus low doses of the anticancer prodrug ifosfamide in patients with advanced, inoperable cancer has been published in the scientific journal Pharmaceutics.
Drug Research > Drug Discovery & Development > News
Ligand signs license deal with Avion for Captisol
By PBR Staff Writer
Ligand Pharmaceuticals (LGND) has signed a commercial license agreement with Avion Pharmaceuticals to develop and commercialize four Captisol-enabled programs.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250